The first Russian patent was included in the EAPO Pharmaceutical Register



This medicine is for the treatment and prevention of myocardial infarction.

The first national patent, information about which was included in the EAPO Pharmaceutical Register, was the patent of the Russian Federation RU 2317990. The owner of the patent is AstraZeneca, one of the leaders in the global pharmaceutical industry.

Patent of the Russian Federation No. 2317990 protects triazolopyrine compounds, a method for their preparation, pharmaceutical compositions based on them, and a method of treatment. The invention is intended for the treatment and prevention of myocardial infarction, cerebral hemorrhage and peripheral vascular thrombotic diseases or for preventing the growth or spread of tumors.

— The first step towards inclusion in the EAPO Pharmaceutical Register by the holders of national patents of Eurasian countries is of great importance. It shows that patent owners regard the Pharmaceutical Register as a necessary tool for protecting their intellectual property, as an important resource for the comprehensive protection of their intellectual property in the Eurasian space. Perhaps as an important step towards obtaining a Eurasian patent, valid in the territory of eight countries, in the future. I am sure that the example of such a large company will inspire both other patent holders and our colleagues from national offices, — said EAPO President Grigory Ivliev.

The EAPO Pharmaceutical Register has been in force since 2021. It includes information about Eurasian patents in the field of pharmaceutic, the subject of which are pharmacologically active ingredients with an assigned INN. This makes it possible for examiners of national offices to use it as a practical tool in assessing the patentability of new inventions, and for patent holders to use it as an additional tool for protecting their intellectual property rights.

In the spring of 2022, at a meeting of the Administrative Council of the Eurasian Patent Organization (EAPO), representatives of eight EAPO member states positively assessed the EAPO initiative to supplement the EAPO Pharmaceutical Register with information on national patents at the request of patent owners.